Drug Profile
PF 258210
Alternative Names: PF-00258210Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Respiration disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Respiration-disorders(Combination therapy, In volunteers) in Singapore (Inhalation, Powder)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Respiration-disorders(Monotherapy, In volunteers) in Singapore (Inhalation, Powder)
- 26 Apr 2010 Pfizer completes a phase I trial in volunteers in Singapore